Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced that it will acquire Kezar Life Sciences for $6.955 in cash per share, plus a contingent value right (CVR) that could increase the purchase price if Kezar meets certain milestones. The cash portion of the deal amounts to approximately $50.93 million, while the CVR provides potential upside tied to the development or sale of Kezar’s lead candidate, zetomipzomib, and proceeds from collaborations with Everest Medicines and Enodia Therapeutics. The transaction is expected to close in the second quarter of 2026, subject to customary regulatory approvals and shareholder consent.
Continue reading for full analysis...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced that Kevin Tang, the company’s chair of the board, will become chief executive officer effective March 23 2026. Tang, a life‑sciences investor who previously chaired La Jolla Pharmaceutical and founded Odonate Therapeutics, will serve without salary, bonuses, or equity awards, a move that signals a focus on shareholder value after a period of executive compensation scrutiny.
Continue reading for full analysis...